Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
Public ClinicalTrials.gov record NCT03867084. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma and Complete Radiological Response After Surgical Resection or Local Ablation (KEYNOTE-937)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will evaluate the safety and efficacy of pembrolizumab (MK-3475) versus placebo as adjuvant therapy in participants with hepatocellular carcinoma (HCC) and complete radiological response after surgical resection or local ablation. The primary hypotheses of this study are that adjuvant pembrolizumab is superior to placebo with respect to: 1) recurrence-free survival (RFS) as assessed by blinded independent central review (BICR); and 2) overall survival (OS).
Study identification
- NCT ID
- NCT03867084
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 959 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 28, 2019 (Actual)
- Primary completion
- Mar 20, 2025 (Actual)
- Completion
- Sep 30, 2025 (Actual)
- Last update posted
- Apr 24, 2026
2019 – 2025
United States locations
- U.S. sites
- 24
- U.S. states
- 17
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Banner MD Anderson Cancer Center ( Site 0026) | Gilbert | Arizona | 85234 | — |
| The University of Arizona Cancer Center - North Campus ( Site 0039) | Tucson | Arizona | 85719 | — |
| City of Hope Medical Center ( Site 0027) | Duarte | California | 91010 | — |
| Smilow Cancer Hospital at Yale New Haven ( Site 0042) | New Haven | Connecticut | 06510 | — |
| Regional Cancer Center ( Site 0054) | Fort Myers | Florida | 33905 | — |
| Indiana University Simon Cancer Center ( Site 0075) | Indianapolis | Indiana | 46202 | — |
| University of Iowa ( Site 0067) | Iowa City | Iowa | 52242 | — |
| James Graham Brown Cancer Center ( Site 0088) | Louisville | Kentucky | 40202 | — |
| University of Louisville ( Site 0059) | Louisville | Kentucky | 40202 | — |
| University Medical Center New Orleans ( Site 0014) | New Orleans | Louisiana | 70112 | — |
| Massachusetts General Hospital ( Site 0062) | Boston | Massachusetts | 02114 | — |
| Boston Medical Center ( Site 0025) | Boston | Massachusetts | 02118 | — |
| Beth Israel Deaconess Medical Ctr. ( Site 0033) | Boston | Massachusetts | 02215 | — |
| University of Massachusetts Worcester ( Site 0017) | Worcester | Massachusetts | 01655 | — |
| Henry Ford Hospital-GI/Hepatology Research ( Site 0047) | Detroit | Michigan | 48202 | — |
| University of New Mexico ( Site 0041) | Albuquerque | New Mexico | 87131 | — |
| North Shore-Long Island Jewish Health System ( Site 0068) | Lake Success | New York | 11042 | — |
| Miami Valley Hospital South ( Site 0093) | Centerville | Ohio | 45459 | — |
| University of Cincinnati Medical Center ( Site 0084) | Cincinnati | Ohio | 45219 | — |
| ProMedica Flower Hospital ( Site 0090) | Sylvania | Ohio | 43560 | — |
| Stephenson Cancer Center ( Site 0045) | Oklahoma City | Oklahoma | 73104 | — |
| Vanderbilt Ingram Cancer Center ( Site 0006) | Nashville | Tennessee | 37232 | — |
| Baylor Scott & White Medical Center - Temple ( Site 0089) | Temple | Texas | 76508 | — |
| Virginia Mason Medical Center ( Site 0028) | Seattle | Washington | 98101 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 225 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03867084, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 24, 2026 · Synced Oct 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03867084 live on ClinicalTrials.gov.